Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 21, 2026, by Jaguar Health, Inc., a Delaware corporation headquartered in San Francisco, California. The report details two significant corporate events: the execution of privately negotiated exchange agreements with Streeterville Capital, LLC, and the adjournment of the Company's 2026 Annual Meeting of Stockholders.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only quantitative financial data disclosed relates to a specific capital transaction:
- Series Q Preferred Stock Issued: 408 shares sold to Streeterville Capital, LLC on May 19, 2026.
- Common Stock Issued: 54,222 shares issued to Streeterville on May 21, 2026.
- Preferred Stock Exchanged: 7.96 outstanding shares of Series Q Preferred Stock were cancelled and retired in exchange for the common stock.
Material Changes
The primary material change reported is the reduction of outstanding Series Q Preferred Stock and the corresponding increase in common stock outstanding through the exchange with Streeterville Capital, LLC. Additionally, the Company's 2026 Annual Meeting, originally called on May 22, 2026, was adjourned to June 2, 2026, at 8:30 a.m. Pacific Time.
Outlook, Risks, and Management Commentary
Annual Meeting Adjournment: The meeting was adjourned following discussions with Nasdaq staff. The Company plans to provide additional information to stockholders regarding certain proposals in the definitive proxy statement (Schedule 14A) before voting occurs. A supplement to the Proxy Statement will be filed prior to the reconvened meeting.
Forward-Looking Statements: The filing contains forward-looking statements regarding the intent to file the Supplement and the reconvened meeting. Management cautions that actual results may differ materially due to risks outlined in the Company's 2025 Form 10-K, including sections on Business, Risk Factors, and Management's Discussion and Analysis.
Investor Verification Checklist
- Verify the terms of the Exchange Agreements (Exhibits 10.1 and 10.2) to understand the valuation and rights associated with the 54,222 common shares issued.
- Review the upcoming Supplement to the Proxy Statement for details on the additional information requested by Nasdaq regarding the Annual Meeting proposals.
- Confirm the impact of the 54,222 new common shares on total outstanding share count and potential dilution.
- Monitor the reconvened Annual Meeting scheduled for June 2, 2026, for voting outcomes on the pending proposals.